Inhibition of [3H]alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: an autoradiographic investigation in human hippocampus - PubMed (original) (raw)
Inhibition of [3H]alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: an autoradiographic investigation in human hippocampus
G Künig et al. Epilepsy Res. 1998 Jul.
Abstract
The interaction of the anticonvulsant valproate with AMPA glutamate receptors in human post mortem hippocampus was investigated. At concentrations of > or = 100 microM valproate decreased binding of 40 nM [3H]AMPA to 45+/-56% of control level (CA 1). Clinically effective brain concentrations for valproate are estimated at 100-200 microM. Our results thus provide evidence that the anticonvulsant effects of valproate may partially be caused by interaction with AMPA receptors.
Similar articles
- AMPA receptor modulation in previously frozen mouse brain sections: opposite effects of calcium in the cortex and hippocampus.
Lapierre L, Valastro B, Miceli D, Massicotte G. Lapierre L, et al. Hippocampus. 2000;10(6):645-53. doi: 10.1002/1098-1063(2000)10:6<645::AID-HIPO1002>3.0.CO;2-U. Hippocampus. 2000. PMID: 11153710 - Autoradiographic characterization of [3H]6-cyano-7-nitroquinoxaline-2,3-dione binding sites in adult chick brain.
Zavitsanou K, Mitsacos A, Kouvelas ED. Zavitsanou K, et al. Neuroscience. 1994 Oct;62(3):955-62. doi: 10.1016/0306-4522(94)90486-3. Neuroscience. 1994. PMID: 7532837 - Septotemporal distribution of [3H]MK-801, [3H]AMPA and [3H]Kainate binding sites in the rat hippocampus.
Martens U, Capito B, Wree A. Martens U, et al. Anat Embryol (Berl). 1998 Sep;198(3):195-204. doi: 10.1007/s004290050177. Anat Embryol (Berl). 1998. PMID: 9764974 - New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors.
Fletcher EJ, Lodge D. Fletcher EJ, et al. Pharmacol Ther. 1996;70(1):65-89. doi: 10.1016/0163-7258(96)00014-9. Pharmacol Ther. 1996. PMID: 8804111 Review. - Psychotropic drug interactions with valproate.
Fleming J, Chetty M. Fleming J, et al. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101. doi: 10.1097/01.wnf.0000154221.37887.73. Clin Neuropharmacol. 2005. PMID: 15795555 Review.
Cited by
- Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.
Lees GJ. Lees GJ. Drugs. 2000 Jan;59(1):33-78. doi: 10.2165/00003495-200059010-00004. Drugs. 2000. PMID: 10718099 Review. - Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats.
Basselin M, Chang L, Chen M, Bell JM, Rapoport SI. Basselin M, et al. Neurochem Res. 2008 Nov;33(11):2229-40. doi: 10.1007/s11064-008-9700-2. Epub 2008 May 7. Neurochem Res. 2008. PMID: 18461450 Free PMC article. - Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
Sanacora G, Zarate CA, Krystal JH, Manji HK. Sanacora G, et al. Nat Rev Drug Discov. 2008 May;7(5):426-37. doi: 10.1038/nrd2462. Nat Rev Drug Discov. 2008. PMID: 18425072 Free PMC article. Review. - Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.
Machado-Vieira R, Zarate CA Jr. Machado-Vieira R, et al. Depress Anxiety. 2011 Apr;28(4):267-81. doi: 10.1002/da.20800. Epub 2011 Feb 24. Depress Anxiety. 2011. PMID: 21456037 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources